Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minerval (2-OHOA) added to radiotherapy and temozolomide for newly diagnosed primary glioblastoma
MOH_2018-11-12_004746Phase 2Recruiting
- Sponsor
- Lipopharma Therapeutics
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 2-hydroxyoleic acid in glioblastoma (GBM) (3 arms), sponsored by Lipopharma Therapeutics. Started Oct 2018; status: recruiting.
02
Drugs
2-hydroxyoleic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on MOH_2018-11-12_004746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-12_004746.